New Approaches on Cancer Immunotherapy

Ho, Jin‐Nyoung; Chan, Li-Chuan; Song, Min Sup; Hung, Mien‐Chie

doi:10.1101/cshperspect.a036863

Cited by 34 publications

(21 citation statements)

References 125 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In recent years, cancer immunotherapy has not only been paid more attention by the growing number of researchers, but also has been widely used in clinical practice ( 47 , 48 ). Although a variety of immunotherapy methods are available to treat tumors, including immune checkpoint inhibitors, cytokine, adoptive cell transfer, dendritic cell vaccines and chimeric antigen receptor T cells, immunotherapy based on immune checkpoint inhibitors have become the focus of attention ( 49 , 50 ). At the same time, tumor ablation has received extensive attention as a promising minimally invasive technique for the treatment of various tumors ( 2 ).…”

Section: Discussionmentioning

confidence: 99%

Knowledge mapping of image-guided tumor ablation and immunity: A bibliometric analysis

et al. 2023

View full text Add to dashboard Cite

BackgroundVarious ablation techniques have been successfully applied in tumor therapy by locally destroying tumor. In the process of tumor ablation, a large number of tumor cell debris is released, which can be used as a source of tumor antigens and trigger a series of immune responses. With the deepening of the research on the immune microenvironment and immunotherapy, researches exploring tumor ablation and immunity are continuously published. However, no research has systematically analyzed the intellectual landscape and emerging trends for tumor ablation and immunity using scientometric analysis. Therefore, this study aimed to conduct a bibliometric analysis to quantify and identify the status quo and trend of tumor ablation and immunity.MethodsData of publications were downloaded from the Web of Science Core Collection database. CiteSpace and VOSviewer were used to conduct bibliometric analysis to evaluate the contribution and co-occurrence relationship of different countries/regions, institutions and authors in the field, and to determine the research hotspots in this field.ResultsBy searching in the database, a total of 3531 English articles published between 2012 and 2021 were obtained. We observed rapid growth in the number of publications since 2012. The two most active countries were China and the United States, with more than 1,000 articles. Chinese Academy of Sciences contributed the most publications (n = 153). Jibing Chen and Xianzheng Zhang might have a keen interest in tumor ablation and immunity, with more publications (n = 14; n = 13). Among the top 10 co-cited authors, Castano AP (284 citations) was ranked first, followed by Agostinis P (270 citations) and Chen Qian (246 citations). According to the co-occurrence and cluster analysis, the results indicated that the focus of research was “photothermal therapy” and “immune checkpoint blockade”.ConclusionsIn the past decade, the neighborhood of tumor ablation domain immunity has been paid more and more attention. Nowadays, the research hotspots in this field are mainly focused on exploring the immunological mechanism in photothermal therapy to improve its efficacy, and the combination of ablation therapy and immune checkpoint inhibitor therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Knowledge mapping of image-guided tumor ablation and immunity: A bibliometric analysis

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Immunotherapy is an effective treatment for cancer, mainly for the clinical treatment of recurrent or metastatic tumors ( Igarashi and Sasada, 2020 ; Quaglino et al, 2020 ). Basic and clinical studies have shown that antitumor immunity plays a key role in the development and progression of cancer ( Cha et al, 2020 ). Patients with UCEC reflect resemble clinical features, but due to molecular heterogeneity, they have distinct clinical results ( Li et al, 2020c ).…”

Section: Discussionmentioning

confidence: 99%

COVID-19–associated lncRNAs as predictors of survival in uterine corpus endometrial carcinoma: A prognostic model

Ding

et al. 2022

Front. Genet.

View full text Add to dashboard Cite

Background: Patients with uterine corpus endometrial carcinoma (UCEC) may be susceptible to the coronavirus disease-2019 (COVID-19). Long non–coding RNAs take on a critical significance in UCEC occurrence, development, and prognosis. Accordingly, this study aimed to develop a novel model related to COVID-19–related lncRNAs for optimizing the prognosis of endometrial carcinoma.Methods: The samples of endometrial carcinoma patients and the relevant clinical data were acquired in the Carcinoma Genome Atlas (TCGA) database. COVID-19–related lncRNAs were analyzed and obtained by coexpression. Univariate, least absolute shrinkage and selection operator (LASSO), and multivariate Cox regression analyses were performed to establish a COVID-19–related lncRNA risk model. Kaplan–Meier analysis, principal component analysis (PCA), and functional enrichment annotation were used to analyze the risk model. Finally, the potential immunotherapeutic signatures and drug sensitivity prediction targeting this model were also discussed.Results: The risk model comprising 10 COVID-19–associated lncRNAs was identified as a predictive ability for overall survival (OS) in UCEC patients. PCA analysis confirmed a reliable clustering ability of the risk model. By regrouping the patients with this model, different clinic-pathological characteristics, immunotherapeutic response, and chemotherapeutics sensitivity were also observed in different groups.Conclusion: This risk model was developed based on COVID-19–associated lncRNAs which would be conducive to the precise treatment of patients with UCEC.

show abstract

“…Therefore, there have been active attempts to restore CTL activity by blocking PD-L1/PD-1 signaling. FDA approved-ICBs, such as nivolumab, pembrolizumab, and atezolizumab, target PD-1 or PD-L1 ( 14 ).…”

Section: The Effect Of Metformin On Anti-tumor Immunitymentioning

confidence: 99%

“…Since T-cells are the main effector of anti-tumor immunity, T-cell activity has been the final target for most FDA-approved cancer immunotherapies [e.g., ICB (Ipilimumab, Nivolumab, Pembrolizumab, and Atezolizumab), dendritic-cell vaccine (Sipuleucel-T), and ACT (Axicabtageneciloleucel, and Tisagenlecleucel)] ( 14 ). However, since TIL activity is effectively inhibited by pro-tumoral TME, the efficacy of current immunotherapies is limited in most solid tumors.…”

Section: Introductionmentioning

confidence: 99%

A new aspect of an old friend: the beneficial effect of metformin on anti-tumor immunity

et al. 2020

Self Cite

View full text Add to dashboard Cite

T-cell-based cancer immunotherapies, such as immune checkpoint blockers (ICBs) and chimeric antigen receptor (CAR)-T-cells, have significant anti-tumor effects against certain types of cancer, providing a new paradigm for cancer treatment. However, the activity of tumor infiltrating T-cells (TILs) can be effectively neutralized in the tumor microenvironment (TME) of most solid tumors, rich in various immunosuppressive factors and cells. Therefore, to improve the clinical outcomes of established T-cell-based immunotherapy, adjuvants that can comprehensively relieve multiple immunosuppressive mechanisms of TME are needed. In this regard, recent studies have revealed that metformin has several beneficial effects on anti-tumor immunity. In this mini-review, we understand the immunosuppressive properties of TME and how metformin comprehensively enhances anti-tumor immunity. Finally, we will discuss this old friend’s potential as an adjuvant for cancer immunotherapy.

show abstract

New Approaches on Cancer Immunotherapy

Cited by 34 publications

References 125 publications

Knowledge mapping of image-guided tumor ablation and immunity: A bibliometric analysis

Knowledge mapping of image-guided tumor ablation and immunity: A bibliometric analysis

COVID-19–associated lncRNAs as predictors of survival in uterine corpus endometrial carcinoma: A prognostic model

A new aspect of an old friend: the beneficial effect of metformin on anti-tumor immunity

Contact Info

Product

Resources

About